Kennesaw, GA—Deerland Probiotics & Enzymes announced its acquisition of Bifodan A/S in a press release. Bifodan, based in Hundested, Denmark, is a life science company specializing in developing, manufacturing, and distributing unique probiotic product solutions as private label dietary supplements, medical devices, and OTC drugs.
Effective with the acquisition, Bifodan is a wholly owned subsidiary of Deerland. Scott Ravech, current Deerland CEO, will continue in that position. Bifodan’s CEO Steen Andersen has been named President Deerland Probiotics & Enzymes International, and will be responsible for the Hundested site and all activity outside the Americas.
Related: Deerland Prebiotic PreforPro Shown to Support Gut Microbiota
Functional Applications for Spore-Forming Probiotics
Beyond Probiotics: Pre-, Syn-, Post-, and Psycho-
“We believe this investment will allow us to bring even greater value to our respective customers and to the enzyme and probiotic industries we serve,” said Ravech in the release. “Deerland and Bifodan are leaders in their respective markets. Bringing together this expertise will benefit both companies, our employees, and our customers.”
“We are excited to join the Deerland organization and have great expectations to leverage the combined competencies of our companies to create a strong global player,” added Andersen.